A court in San Diego has stated that part of the suit between Quidel and Beckman is void as a matter of law.

The discussion draft includes the regulatory proposals, including precertification, the FDA provided to legislators in a technical assistance document.

At the Business in Personalized Medicine Summit last week, the company also said it has generated promising data from a pilot study for early detection of lung cancer.

Following promising data from its Circulating Cell-free Genome Atlas study, the firm decided to pivot its breast cancer trial to support its multi-cancer test.